Skip to main content

Table 1 Baseline demographics and lesion characteristics

From: Zilver PTX Post-market Surveillance Study of Paclitaxel-Eluting Stents for Treating Femoropopliteal Artery Disease in Japan: 2-Year Results

Patient characteristics
Patients 905
Mean age (years) 73.5 ± 8.5 (905)
Men 70.3 (636)
Diabetes 58.8 (532)
Hypertension 85.4 (773)
Hypercholesterolemia 60.8 (550)
Chronic kidney disease 43.6 (395)
eGFR < 60 mL/min/1.73 m2 and/or dialysis 35.5 (321)
Pulmonary disease 8.1 (73)
Lesion characteristics
Lesions 1080
Lesion length (cm) 14.6 ± 9.6 (1079)
 Lesions > 15 cm 41.9 (453)
 Lesions > 20 cm 29.7 (321)
Lesion locationa  
 Proximal SFA 61.1 (657)
 Distal SFA 64.5 (693)
 Popliteal 9.4 (101)
Total occlusion 41.5 (448)
In-stent restenosis 18.7 (202)
Percent diameter stenosis 91.7 ± 10.8 (1080)
Reference vessel diameter (mm) 5.7 ± 0.9 (1079)
Critical limb ischemia (Rutherford classes 4–6)b 21.4 (218)
Number of patent runoff vesselsc  
 0 6.6 (71)
 1 31.9 (343)
 2 32.5 (349)
 ≥ 3 29.0 (311)
  1. Values are mean ± SD or % (n)
  2. eGFR estimated glomerular filtration rate, SFA superficial femoral artery
  3. aOf the 1080 lesions in this study, 376 lesions span more than one segment
  4. bRutherford classification data not available for 60 lesions
  5. cData not available for six lesions